Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application.
Bladder cancer is a common and frequently lethal cancer. Natural history studies indicate two distinct clinical and molecular entities corresponding to invasive and non-muscle invasive disease. The high frequency of recurrence of noninvasive bladder cancer and poor survival rate of invasive bladder cancer emphasizes the need for novel therapeutic approaches. These mechanisms of tumor development and promotion in bladder cancer are strongly associated with several growth factor pathways including the fibroblast, epidermal, and the vascular endothelial growth factor pathways. In this review, efforts to translate the growing body of basic science research of novel treatments into clinical applications will be explored.
Yang
Xiaoping
X
Department of Medicine, Division of Medical Oncology, University of Colorado Denver School of Medicine, Aurora, CO, 80045, USA.
Flaig
Thomas W
TW
D002986:Clinical Trials as Topic; D066246:ErbB Receptors / Q000627:therapeutic use*; D006801:Humans; D017468:Receptors, Fibroblast Growth Factor / Q000627:therapeutic use*; D057170:Translational Research, Biomedical / Q000379:methods; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*
D017468:Receptors, Fibroblast Growth Factor; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors